GNOM
Performance
GNOM (GNOM) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
GNOM (GNOM) is a publicly traded company on the US stock market.
No strong bullish signals found
- Price is near its 52-week high — limited near-term upside, higher pullback risk
Verdict
Caution
More risks than strengths. Consider waiting for fundamentals to improve before adding.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
Current DY
—
5Y Avg Annual
$0.1558
Last Payment
$0.5910
Ex-Date
12/30/2025
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest12/30/2025 | 01/13/2026 | $0.5910 | 4.74% |
06/27/2025 | 07/11/2025 | $0.0320 | 0.26% |
12/30/2021 | 01/13/2022 | $0.0280 | 0.22% |
12/30/2020 | 01/13/2021 | $0.1280 | 1.03% |
Magic Number
Shares needed to self-fund your next purchase
$49.90
Price
$0.5910
Last div. (yearly)
85
shares
Own 85 GNOM shares ($4,241.08) and each yearly dividend pays for 1 new share — the snowball runs on its own.
Investment target
$4,241.08
New shares / year
+1 shares
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $49.90
Graham Number
√(22.5 × EPS × Book Value)
N/A
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$4.33
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
2/10
67% score
Pays dividends
6Y hist.6+ years of dividend history
Dividend consistency (5Y+)
6 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
Return on equity — measures how efficiently capital is used
Positive profit margin
Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
Annual revenue must be growing compared to the prior year
Earnings growth (annual)
Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
Low financial leverage reduces risk of distress
Current ratio above 1
Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$461K/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
Stock must distribute income to shareholders
Related Assets
About GNOM
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.